Aldeyra Therapeutics Inc

Chiusa

1.83 2.81

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.72

Massimo

1.83

Metriche Chiave

By Trading Economics

Entrata

-23T

-3.5M

EPS

-0.06

Dipendenti

7

EBITDA

3M

-2.9M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+9.29% upside

Dividendi

By Acuity

Utili prossimi

5 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

26M

124M

Apertura precedente

-0.98

Chiusura precedente

1.83

Aldeyra Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 giu 2026, 23:51 UTC

"Bitcoin rises as Ethereum falls amid pivotal AI earnings reports, while U.S. credit rating remains stable and China's industrial profits soar."

27 giu 2026, 23:51 UTC

China's industrial profits rise 18.8% amid AI investments; U.S. credit rating affirmed at AA+ as markets brace for modest growth and pivotal Meta earnings report.

27 giu 2026, 23:51 UTC

Cryptocurrency market shows mixed signals as investors brace for key AI earnings reports and upcoming economic indicators amid cautious U.S. growth outlook.

27 giu 2026, 23:51 UTC

Mixed cryptocurrency performance reflects cautious investor sentiment ahead of key economic indicators and AI earnings reports, while U.S. credit rating remains stable amid inflation concerns.

27 giu 2026, 23:51 UTC

Bitcoin is trading higher since Friday's close, remaining flat during the current session. The price fluctuated within a routine range today.

27 giu 2026, 23:42 UTC

U.S. Labor Force Participation Rate Release on July 2, 2026: Market Cautious Amid Declining Employee Confidence and Legislative Changes Impacting Employment Dynamics.

27 giu 2026, 23:42 UTC

Market Awaits BoC Governor Macklem's Speech on Interest Rate Policy Amid Economic Uncertainties

27 giu 2026, 23:42 UTC

Market Eyes BoE Governor Bailey's July Speech for Insights on UK Interest Rates Amid Global Monetary Policy Shifts.

27 giu 2026, 23:42 UTC

Market Anticipates 0.3% Increase in U.S. Average Hourly Earnings Amid Wage Growth Concerns and Inflation Pressures Ahead of July Release.

27 giu 2026, 23:42 UTC

U.S. Unemployment Rate Release on July 2, 2026 Expected at 4.3%, Amid Concerns Over Employee Confidence and Potential Minimum Wage Legislation Impacting Markets

27 giu 2026, 23:42 UTC

Market Anticipates 114K Job Additions in Upcoming June NFP Report Amid Mixed Economic Sentiment and Inflation Concerns.

27 giu 2026, 23:42 UTC

Market Awaits Key Average Hourly Earnings Data Amidst Rising Inflation Concerns and Potential Federal Reserve Rate Implications on July 2, 2026.

27 giu 2026, 23:31 UTC

Mexican Consumer Confidence Expected to Remain Low Amid Economic Challenges Ahead of July 3 Data Release.

27 giu 2026, 23:11 UTC

ADP Employment Change Report Forecasts 118,000 Job Increase Amid Cautious Optimism in Labor Market Ahead of July Release.

27 giu 2026, 23:11 UTC

Correlated Moves

S&P 500 Index declines in after-market trading, reflecting cautious sentiment ahead of upcoming earnings reports from AI-linked companies like Meta.

27 giu 2026, 23:11 UTC

Correlated Moves

The Russell 2000 Index is lower in after-market trading, reflecting broader market sentiment amid upcoming earnings reports from AI-linked companies.

27 giu 2026, 23:11 UTC

Correlated Moves

The Dow Jones Index is lower in after-market hours, reflecting unusual trading activity and broader declines seen in the Russell 2000 Index.

27 giu 2026, 23:11 UTC

The FTSE 100 Index is lower in after-market hours, reflecting a dip since Friday's close. Anticipation of corporate earnings reports may influence market sentiment.

27 giu 2026, 23:11 UTC

Correlated Moves

The Nasdaq 100 Index is lower during after-market hours, continuing a downward trend since Friday's close amid broader market weakness and upcoming earnings anticipation.

27 giu 2026, 23:02 UTC

Canada's May GDP report set for June 30, with a projected growth of 0.4% amid mixed stock performance and trade uncertainties.

27 giu 2026, 22:32 UTC

Germany's June 30 inflation rate forecasted to rise by 0.1%, raising concerns over persistent inflation and potential ECB monetary policy shifts amid global economic pressures.

27 giu 2026, 22:32 UTC

Germany's June 2026 Inflation Rate Release Expected at 2.5% Amid Rising Global Price Pressures and Cautious Market Sentiment

27 giu 2026, 22:32 UTC

Japan's Tankan Large Manufacturers Index set for June 30, with cautious market sentiment amid stock declines and mixed economic signals.

27 giu 2026, 22:32 UTC

South Africa's Upcoming Balance of Trade Data Expected to Show Significant Shift Amid Rising Imports and Mixed Export Performance

27 giu 2026, 22:21 UTC

Brazil's Central Bank to Provide Key Insights on Interest Rate Outlook Amid Rising Global Pressures in June 29 Readout.

27 giu 2026, 22:11 UTC

Japan's Industrial Production Expected to Rise 1.1% in May Amid Mixed Market Sentiment and Economic Concerns

27 giu 2026, 22:02 UTC

South Korea's June 2026 Inflation Rate Release Sparks Market Caution Amid Rising Price Pressures and Regional Economic Concerns.

27 giu 2026, 21:51 UTC

Japan's Retail Sales YoY data for May set to release on June 28, with a projected growth of 3.2% amid mixed market sentiment and inflation concerns.

27 giu 2026, 21:51 UTC

Japan's Unemployment Rate Expected to Stabilize at 2.5% Amid Mixed Economic Sentiment and Market Volatility

27 giu 2026, 21:41 UTC

Cautious Sentiment Surrounds Upcoming Ai Group Industry Index Release Amid Ongoing Economic Challenges in Australia

Confronto tra pari

Modifica del prezzo

Aldeyra Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

9.29% in crescita

Previsioni per 12 mesi

Media 2 USD  9.29%

Alto 2 USD

Basso 2 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Aldeyra Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

0

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
help-icon Live chat